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Background: Cell-wall components of Gram-positive
and Gram-negative bacteria induce the production of
cytokines  in  human peripheral  blood mononuclear
cells. These cytokines are the main mediators of local
or systemic inflammatory reaction that can contrib-
ute to the development of innate immunity.
Aims:  This  study  was  performed  to  analyze  the
involvement  of  CD14  molecule  in  the  activation  of
human monocytes by peptidoglycan monomer (PGM)
obtained by biosynthesis from culture  fluid of pen-
icillin-treated  Brevibacterium  divaricatum  NRLL-
2311.
Methods: Cytokine release of interleukin (IL)-1, IL-6
and tumor necrosis factor-alpha from human mono-
cytes  via  soluble  CD14  (sCD14)  or  membrane-asso-
ciated (mCD14) receptor using anti-CD14 monoclonal
antibody (MEM-18)  or  lipid  A structure  (compound
406) was measured in bioassays.
Results:  The  results  demonstrated  that  PGM  in  the
presence  of human serum might induce the mono-
kine release in a dose-dependent manner. The addi-
tion  of  sCD14  at  physiologic  concentrations
enhanced the PGM-induced monokine release, while
the  monokine  inducing  capacity  of  PGM  in  the
presence of sCD14 was inhibited by MEM-18. Effects
of PGM were also blocked by glycolipid, compound
406, suggesting the involvement of binding structures
similar to those for lipopolysaccharide.
Conclusion: Activation of human monocytes by PGM
involves  both  forms  of  CD14  molecule,  sCD14  and
mCD14.
Keywords: Peptidoglycan monomer, Peptidoglycan, Lipo-
polysaccharide,  CD14,  Membrane  CD14,  Soluble  CD14,
Anti-CD14  monoclonal  antibody,  Compound  406,  Mono-
cytes, Cytokines
Introduction
Cell  wall  components of  Gram-negative and  Gram-
positive  bacteria  have  been  reported  to  induce
inflammatory  responses  in  vivo,  as  well  as  in
vitro.1–5 When localized, this inflammation helps to
eradicate the invading organisms at the infected site,
but in severe situations the release of soluble cellular
mediators and dysfunction of numerous host defense
factors  may  result  in  systemic  inflammation  that
causes  organ  damage,  sepsis,  and  death.  Septic
shock is a classical response to severe infections due
to  Gram-negative  bacteria and its  principal  compo-
nent  lipopolysaccharide  (LPS).6–8 Similar  events,
however,  may  also  be  provoked  by  Gram-positive
bacteria9 containing,  in  cell  walls,  predominantly
thick  peptidoglycans  (PG),  which  may  also  be
obtained in  the soluble  form  (sPG),  after  the treat-
ment  of  growing  bacteria  by  b -lactam  antibio-
tics.10,11 Chemically,  PG  is  an  alternating  linked
N-acetylmuramyl  and  N-acetylglucosaminyl  glycan
whose  residues  are  cross-linked  by  short  pep-
tides.10–13 Soluble PG, obtained from staphylococci,
consists  of  disaccharide–peptapeptide  polymers
linked  together  via  1–4
b -glycosidic  bonds,  without
the interpeptide bridges,  due to the action of  pen-
icillin.10–13 All  these  components,  similar  to  lipo-
teichoic  acid  (LTA),  lipoarabinomannan,  and  other
glycosyl  residue-containing  compounds,  stimulate
the release of proinflammatory mediators in the host
from  various  cell  types.1–9 However,  although  it  is
evident that PG has, in  principle, the same inflam-
matory  activity  as LPS, the  knowledge  on  the con-
tribution of PG in distinct inflammatory reaction, as
well as the mechanisms of its signal transduction in
lymphoid  cells,  is  limited.  Evidence  shows  that
activation  of  cells  by  PG  is  a  receptor-mediated
process involving the binding of PG to membranous
CD14  (mCD14),1–14 and  to  the  additional  signal
transducing  receptors,  belonging  to  the  Toll-like
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and  PG-mediated  signals  seem  to  activate  similar
types  of  receptors,  the  type  of  signal  and  co-
receptors  may  differ,  resulting  in  different  require-
ment  of  serum  factors  and  activation  of  different
sequences in the region of CD14.20,21
Since there is still a paucity of data regarding the
mechanisms  leading  to  inflammatory  response
induced by Gram-positive bacteria, in spite of the fact
that  in  recent  years  they  have  caused  nosocomial
infections  and  shock  more  frequently  than  Gram-
negative bacteria,22 in the present study we tested the
effects of peptidoglycan monomer (PGM), obtained
by  biosynthesis  from  culture  fluids  of  penicillin-
treated Brevibacterium divaricatum NRRL-231123,24
on cytokine production of human peripheral blood
mononuclear cells and on the involvement of soluble
(sCD14) and mCD14 in these events. PGM represents
a  water-soluble  monomeric  structural  subunit  of
the  polymeric  PG,  consisting  of  b 1,4-linked
N-acetylmuramic  acid-N-acetyl-D-glucosamine  disac-
charide carrying the pentapeptid. Its immunostimu-
lating and anti-metastatic activities were emphasized
in many experimental protocols,25–28 but its action is
still  unclear.  The  data  showed  that  PGM  has  a
cytokine-stimulating  capacity  in  vitro, leading  to
release of interleukin (IL)-1, IL-6, and tumor necrosis
factor-a (TNF-a ) in the presence of human serum or
sCD14. Since the effects were blocked by anti-CD14
monoclonal  antibodies  (MEM-18)  and  by  lipid  A
partial  structure  (compound  406),  the  data  also
suggest  the  involvement  of  both  forms  of  CD14
molecules in these events.
Materials and methods
Cell wall components
PGM  (N-acetyl-glucosaminyl-b -(1® 4)-N-acetyl-mura-
moyl-L-alanyl-D-isoglutaminyl- L-meso-diaminopimelyl-
(D-amide)-(L)-D-alanyl-D-alanine), a disaccharide penta-
peptide from Gram-positive bacteria B. divaricatum,
was isolated and purified as described elsewhere.23,24
It contained less than 2.25pg of endotoxin permg of
PGM, which was determined by the Limulus Amebo-
cyte  Lysate  (LAL)  assay  (Haemochrom  Diagnostica
GmbH,  Essen,  Germany).  LPS  was  isolated  from
Salmonella friedenau and purified by the phenol–
chloroform–petroleum ether method.29 This prepara-
tion contained less than 0.2% of protein and nucleic
acids as determined by chemical analysis.
Synthetic compound 406 (precursor Ia), a tetra-acyl
partial structure of Escherichia coli hexa-acyl lipid A
lacking  dodecanoic  and  tetradecanoic  acids,  was
synthesized  as  described  previously.30 Compound
406 was kindly provided by Dr S. Kusumoto, Depart-
ment  of  Chemistry,  Faculty  of  Science,  Osaka  Uni-
versity, Osaka, Japan.
Antibodies
The  CD14-specific  monoclonal  antibody  (murine
hybridoma  MEM-18  producing  immunoglobulin
(Ig)G1 monoclonal antibody) was kindly provided by
Dr V´ aclov  HorejÆs´ õ ,  Institute  of  Molecular  Genetics,
Academy of Sciences of the Czech Republic, Prague,
Czech  Republic.31 Purified  mouse  IgG1  (MOPC21;
Sigma GmbH, Deisenhofen, Germany) was used as an
antibody isotype control.
Recombinant human soluble CD14
Recombinant  human  soluble  CD14  (sCD14)32 was
purified  from  serum-free  culture  supernatant  of
sCD14-transfected CHO cells by affinity  chromatog-
raphy  (kindly  provided  by  Dr  F.  Stelter,  Institut  of
Immunology and Transfusion Medicine, University of
Greifswald, Greifswald, Germany).
Cell isolation and induction of TNF, IL-1 and
IL-6 release
Human blood from different healthy donors (permis-
sion was obtained from the Local Ethical Committee)
was collected in heparin (10U/ml). The mononuclear
cells  (MNC)  were  isolated  by  density-gradient  cen-
trifugation on Ficoll-Paque (Pharmacia, Uppsala, Swe-
den)  as  described elsewhere.33 After being  washed
three times, MNC (4 ´ 106/ml)  were suspended in
RPMI 1640 supplemented with 100U/ml of penicillin
and 100 m g/ml of streptomycin (RPMI-1640-M). The
cells  were  stimulated  for  8h  at  37°C  (5%  CO2)  in
200 m l cultures with an appropriate cytokine inducer
in the presence or absence of 10% heat-inactivated
human  serum  (HS)  in  U-bottomed microtiter plates
(Greiner,  N¨ urtingen,  Germany).  All  cultures  were
carried  out  in  triplicate.  After  incubation,  super-
natants  were  harvested  and  stored  at  –20°C  until
analyzed for IL-1, IL-6 or TNF activity. In the inhibition
experiments  with  anti-CD14  monoclonal  antibody
(mAb) or compound 406, MNC were first pretreated
for 1h with these compounds on ice, after which the
stimulus (PGM or LPS) was added. To investigate the
effect of sCD14, PGM or LPS were first preincubated
for  3h  with  sCD14  and  then  added to  MNC  (4 ´
106/ml) in RPMI-1640-M without HS.
Determination of TNF, IL-1 and IL-6 bioactivity
TNF  and  IL-1  were  determined  in  bioassays  as
described  elsewhere.33,34 In  brief,  TNF  cytotoxic
activity in culture supernatants was measured using
the TNF-sensitive L929 fibrosarcoma cell line. In the
IL-1  bioassay,  the  proliferation-inducing  activity  of
the  culture  supernatant  from  human  foreskin  der-
mal  fibroblasts  was  determined.34 IL-6  activity  was
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proliferation  assay.35 The TNF,  IL-1,  and  IL-6  activ-
ities  in  the  samples  were  determined  by  probit
analysis  using  a  standard  preparation  of  recombi-
nant human TNF-a , IL-1b or IL-6, respectively.36 The
results were calculated to units per milliliter of TNF-
a ,  IL-1,  and  IL-6,  respectively. The  following  agents
did  not  induce  release  of  these  cytokines  after
addition  to  monocytes:  human  serum,  compound
406, anti-CD14mAb (MEM-18), and human recombi-
nant soluble sCD14.
Statistical analysis
Results were analyzed using the SigmaPlot Scientific
Graphing  System  Version  5.0  (Jandel  Corporation,
Activation of human monocytes by PGM
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FIG. 1. Induction of IL-6 and IL-1 release from mononuclear cells (MNC) by peptidoglycan monomer (PGM) in the presence or
absence of human serum (HS). MNC (4 ´ 10
6/ml) were stimulated with increasing concentrations of PGM in the presence or
absence of 10% HS for 8h. The supernatants were harvested, and (A) IL-6 or (B) IL-1 were measured in bioassays. The data
represent the mean of triplicates ± SEM from one of three identical experiments. * p < 0.05, ** p < 0.01, PGM + 10% HS versus
PGM without (w/o) 10% HS.USA). The test for significance used in all cases was
Student’s t-test.
Results
PGM induces IL-6 and IL-1 release from
cultured MNC
Human  MNC  were  treated  for  8h  with  various
concentrations of  PGM in the presence or absence
of  10%  HS. As shown in  Figure  1,  PGM stimulated
the release of only  small  amounts of IL-6  (Fig.  1A)
or  IL-1  (Fig.  1B)  in  the  absence  of  HS.  However,
after  the  addition  of  10%  HS,  the  statistically
significant (p < 0.05 and p < 0.01)  dose-dependent
increase in the cytokine concentrations was noticed
in  supernatants  of  PGM-stimulated  MNC  (Fig.  1).
A  similar  dose-dependent  effect  of  PGM  was
obtained on the secretion of TNF (data not shown),
pointing  to  the  role  of  sCD14  in  PGM-induced
release  of  inflammatory  cytokines  from  human
monocytes.
sCD14 increases both the PGM- and LPS-induced
IL-1  release  from  human  monocytes,  and  anti-
CD14mAb inhibits this process
To  prove  the  role  of  sCD14  in  PGM-induced
release of  monokines and  to compare this  process
with  that  induced  by  LPS,  PGM  or  LPS  were  pre-
incubated  with  sCD14  for  3h  and  then  added  to
cultures  of  human  monocytes  in  additional  experi-
ments.  The  concentration  of  IL-1  found  in  these
cultures was compared with that found  in  cultures
without added sCD14, with those treated with anti-
CD14mAb  MEM-18,  and  with  those  treated  with
anti-IgG1mAb. As presented in Table 1, the addition
of  sCD14  significantly  enhanced  the  potential  of
both PGM (p < 0.001) and LPS (p < 0.001) to release
the  IL-1  from  monocytes,  and  anti-CD14mAb  (sig-
nificantly, p < 0.001) almost completely blocked this
process,  while  an  isotype  control  (anti-IgG1mAb)
did  not  block  PGM-  or  LPS-induced  cytokine
production.
Anti-CD14mAb inhibits PGM- and LPS-induced
TNF release from MNC
To  elucidate  the  potential  role  of  mCD14,  in  the
further  experiment,  we  preincubated  human  MNC
with  increasing  concentrations  of  anti-CD14mAb
(MEM-18)  or  anti-IgG1mAb  before  the  addition  of
PGM (Fig. 2A) or LPS (Fig. 2B). As shown in Fig. 2A,B,
anti-CD14mAb significantly blocked the TNF produc-
tion in supernatants of PGM (p < 0.01) or LPS (p <
0.01) stimulated cultures, while an isotype control did
not have an inhibitory effect on PGM- or LPS-induced
cytokine  production.  This  indicates  that  anti-
CD14mAb  may  abolish  PGM-induced  and  LPS-
induced TNF production.
The release of TNF from MNC induced by PGM or
LPS  was  completely  inhibited  by  lipid  A  partial
structure (compound 406)
To partially define the PGM binding structures on
the  membrane,  human  MNC  were  pretreated  with
increasing concentrations of compound 406, which is
a  partial  lipid  A  structure.  The  data  showed  that
compound 406 was able to significantly decrease or
abolish (p < 0.001) both PGM- and LPS-induced TNF
production (Fig. 3), indicating that PGM uses similar
receptor structures  as  LPS  during  the  activation of
human monocytes.
Discussion
In  contrast  to  Gram-negative  bacteria,  the  knowl-
edge  about  the  cytokine  induction  due  to  the
adhesion of Gram-positive bacteria to human MNC is
limited and concentrated mostly on the mechanisms
of  action  of  sPG,  muramyl  dipeptide  (MDP)  or
LTA.2,5,9–13,16,19 The  signaling  mechanisms  induced
by water-soluble, monomeric glycopeptides, such as
PGM,  are  even  less  known,  although  it  has  been
repeatedly shown that this product might have very
useful  immunostimulating  abilities.24–28 The  data
presented herein therefore represent, to our knowl-
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Table 1. The effects of soluble CD14 (sCD14) and anti-CD14 monoclonal antibody (MEM-18) on
IL-1 release from human mononuclear cells (MNC) stimulated with peptidoglycan monomer
(PGM) or lipopolysaccharide (LPS)
Stimulation of MNC in the presence of: IL-1 release (U/ml) after stimulation
with:
PGM LPS
Without sCD14 166 ± 7 188 ± 8
sCD14 456 ± 5† 447 ± 9†
Anti-CD14 + sCD14 24 ± 2* 12 ± 2*
IgG1 + sCD14 445 ± 6 453 ± 7
The results are means SEM of triplicates from one out of three separate experiments.
*p < 0.001 versus the same substance with IgG1 + sCD14; † p < 0.001 versus the same substance without
sCD14.edge,  the  first  evidence  of  the  CD14-dependent
cytokine production induced by PGM (disaccharide–
pentapeptide) on human  MNC. The  results  empha-
size that HS  increases PGM-induced monokine pro-
duction  by  human  monocytes  (Fig.  1),  and  clearly
show  that  preincubation  with  sCD14  enhances,
while  anti-CD14mAb  (MEM-18)  blocks,  the  PGM-
induced release of IL-1 (Table 1). Furthermore, since
it was found that MEM-18, similar to a lipid A partial
structure  (compound  406)  (Fig.  3),  may  block  the
biological activity of PGM (Fig. 2), our data suggest
that  mCD14  is  also  involved  in  the  PGM-induced
cytokine release from MNC. Similar to this, unpub-
lished data show that cytokine production in human
Activation of human monocytes by PGM
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FIG. 2. Inhibition of peptidoglycan monomer (PGM)- and lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF) release
in mononuclear cells (MNC) by anti-CD14 monoclonal antibody (mAb) (MEM-18). MNC (4 ´ 10
6/ml) were preincubated with
increasing concentrations of anti-CD14mAb (MEM-18) or purified mouse IgG1 (MOPC21), which was used as an antibody
isotype control for 1h at 4°C before stimulation with (A) PGM (30m g/ml) or (B) LPS (10ng/ml). After 8h of incubation (in the
presence of 10% human serum), supernatants were harvested and TNF activity was determined in the bioassay. Results
represent the mean of triplicates ± SEM from one of three identical experiments. * p < 0.05, ** p < 0.01, PGM + anti-CD14mAb
versus PGM + IgG1, LPS + anti-CD14 versus LPS + IgG1.monocytes  induced  by  MDP  can  be  inhibited  by
anti-CD14mAb  (A.J.  Ulmer,  personal  communica-
tion). Taken together, the data point to the similarity
of  action  between  PGM,  MDP,  sPG  and  LPS,  and
other bacterial products  supporting  the  hypothesis
that CD14 functions as a ‘pattern recognition recep-
tor’,14 which probably recognizes shared features of
all these agents. Moreover, similar to as it was shown
for other Gram-positive peptidoglycans,10 the proin-
flammatory  effects  of  PGM  were  less  emphasized
than that induced by LPS, since it was noticed in the
presence of human serum that, for optimal cytokine
production  from  the  peripheral  blood  MNC,  an
approximately  105 times  higher  concentration  of
PGM  than  of  LPS  (4  log  difference  (m g/ml))  is
required  (unpublished  data).  The  observed  differ-
ence  has  been  attempted  to  be  explained  by  the
existence  of  low  affinity  binding  interaction
between  PGM  and  CD14  molecule,10–12 as  well  as
by the hypothesis that PG is either less active than
LPS  or  only  a  part  of  PG  is  required  for  PBMC
activation.37
Our  data obtained with PGM  are  in  close  agree-
ment  with  results  published  by Weideman  et  al.,10
which  show  similar  binding  characteristics of  sPG.
However,  in  the  literature  there  is  some  disagree-
ment about the determination of structures responsi-
ble  for  the  activation  of  human  monocytes  by
products  of  Gram-positive  bacteria. Thus,  although
our  data  show  that  PGM,  as  the  hydrophilic  dis-
accharide–pentapeptide, has similar effects as hydro-
philic  N-acetylmuramyl-L-alanyl-D-isoglutamine  or
MDP,  which  in  binding  inhibition  studies  was  also
able to block the binding of fluorescein isothiocya-
nate-labeled  sPG  to  human  monocytes,10 in  other
experiments using the gel shift assay it was shown
that soluble MDP did not bind to sCD14 and did not
inhibit binding of sPG or LPS to sCD14.11 The reason
for this difference is unclear, but it was hypothesized
that polymeric, aggregated or solid–phase bound PG
or MDP should be  formed for high affinity binding
to  CD14  in  a  gel  shift  assay,  which  might  not  be
created after  the  use  of  very  hydrophilic  synthetic
PG fragments.11 This is also supported by  our data
showing that PGM also does not inhibit binding of
sPG or LPS to sCD14 in the gel shift assay (unpub-
lished data). As further support of our data, pointing
to activities of soluble PGM, it was recently empha-
sized that digestion products of Streptococcus pneu-
moniae cell  walls  of  a  molecular  weight  between
600  and  15,000  might  have  different  proinflamma-
tory activities.37 Thus, a simple stem peptide (Mr <
750) was 10-fold less active than undigested peptido-
glycans,  in  contrast  to  tripeptides  (Mr >  1000),
which  were  100-fold  more  potent  than  the  native
material.  Moreover,  while  one  dipeptide  was  inac-
tive,  two  tripeptides  were  active,  pointing  to  the
possibility  that  complex  branched  peptides,  which
represent only 2% of the total material, were respon-
sible  for  peptidoglycan-induced  inflammation.
Owing  to  these  facts,  it  was  proposed  that,  to
stimulate  target cells,  both soluble  and cross-linked
peptide must present at least three stem peptides in
close proximity.37
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FIG. 3. Inhibition of tumor necrosis factor (TNF) release induced by peptidoglycan monomer (PGM) and lipopolysaccharide
(LPS)  from  mononuclear  cells  (MNC)  by  the  compound  406.  MNC  (4  ´ 10
6/ml)  were  preincubated  with  increasing
concentrations of compound 406 for 1h at 4°C before stimulation with PGM (30m g/ml) or LPS (10ng/ml). After 8h of incubation
(in the presence of human serum), supernatants were harvested and TNF  activity was detected in the bioassay. Results
represent the mean of triplicates ± SEM from one of three identical experiments. *** p < 0.001, PGM versus PGM  with
compound 406; xxx p < 0.001, LPS versus LPS with compound 406.Recent studies also provided unequivocal evidence
that, for cellular responsiveness to sPG, the N-terminal
151 amino acids of mCD145,11 were sufficient, but the
binding characteristics of hydrosoluble PGM were not
fully  elucidated.  Our  finding  of  dose-dependent,
saturable,  and  anti-CD14  sensitive  effects  of  PGM,
however,  directly  points  to  involvement  of  CD14
(Figs.  1  and  2,  and  Table  1).  Furthermore,  since
cytokine production induced by PGM was blocked by
MEM-18 (Fig. 2), whose epitope is located between
amino acids 51 and 64, there is also some possibility
that these fragments were particularly responsible for
the effects of our immunostimulating agent, similarly
as it was found for sPG and LPS.11 Additionally, owing
to the fact that there is structural similarity between
PGM and lipid A with regard to GlcNAc-MurNAc and
(GlcNAc-MurNac)2, respectively, it could be hypothe-
sized  that  active  parts  of  PGM  were  hydrophilic
domains,  exposed  on  the  surface  and  available  for
binding to CD14.
Taken together, although further characteristics of
the binding of PGM remain to be elucidated, our data
provide the first evidence that, in  the induction of
cytokine production in human monocytes, not only
the polymeric  sPG, but also the monomeric hydro-
soluble  PGM  are  involved.  For  optimal  activation,
PGM required the presence of sCD14 or other human
serum  components  and  mCD14.  In  the  further
experiments, it must  be clarified whether CD14 in
these events acts as a ‘pattern recognition’ receptor,14
an unspecific  carrier molecule,  or as  a  contributor
that,  together  with  LPS-binding  protein  (LBP)  in  a
‘combinatorial’ scheme, participates in recognition of
these and other bacterial products.3,11,14
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